{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T02:04:17Z","timestamp":1768010657702,"version":"3.49.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,8,20]],"date-time":"2020-08-20T00:00:00Z","timestamp":1597881600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,8,20]],"date-time":"2020-08-20T00:00:00Z","timestamp":1597881600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005357","name":"Agent\u00fara na Podporu V\u00fdskumu a V\u00fdvoja","doi-asserted-by":"publisher","award":["15-0086"],"award-info":[{"award-number":["15-0086"]}],"id":[{"id":"10.13039\/501100005357","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005357","name":"Agent\u00fara na Podporu V\u00fdskumu a V\u00fdvoja","doi-asserted-by":"publisher","award":["19-0411"],"award-info":[{"award-number":["19-0411"]}],"id":[{"id":"10.13039\/501100005357","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006109","name":"Vedeck\u00e1 Grantov\u00e1 Agent\u00fara M\u0160VVa\u0160 SR a SAV","doi-asserted-by":"publisher","award":["1\/0327\/19"],"award-info":[{"award-number":["1\/0327\/19"]}],"id":[{"id":"10.13039\/501100006109","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006109","name":"Vedeck\u00e1 Grantov\u00e1 Agent\u00fara M\u0160VVa\u0160 SR a SAV","doi-asserted-by":"publisher","award":["1\/0174\/19"],"award-info":[{"award-number":["1\/0174\/19"]}],"id":[{"id":"10.13039\/501100006109","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006109","name":"Vedeck\u00e1 Grantov\u00e1 Agent\u00fara M\u0160VVa\u0160 SR a SAV","doi-asserted-by":"publisher","award":["1\/0043\/18"],"award-info":[{"award-number":["1\/0043\/18"]}],"id":[{"id":"10.13039\/501100006109","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Survivors of germ-cell tumors (GCT) may suffer from long-term adverse consequences. Our study was conducted to assess a long-term sexual functioning in GCT survivors.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>GCT survivors (<jats:italic>N<\/jats:italic>\u2009=\u2009170) from the National Cancer Institute in Slovakia completed a Sexual Function Questionnaire that was modified from PROMIS Sexual Function and Satisfaction Questionnaire 9-year median follow up (range 5\u201332) as a primary exploratory aim. Study groups consisted of 17 survivors (10%) who had active surveillance (AS, controls), and 153 (90%) survivors who received treatment beyond orchiectomy (Tx), including cisplatin-based chemotherapy (CT, <jats:italic>N<\/jats:italic>\u2009=\u2009132; 78%), radiotherapy to the retroperitoneal lymph nodes (RT, <jats:italic>N<\/jats:italic>\u2009=\u200912; 7%) or both (CTRT, <jats:italic>N<\/jats:italic>\u2009=\u20099; 5%).<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>In univariate analysis, treatment of any type resulted in difficulty to maintain erection during sexual intercourse compared to patients treated with AS (<jats:italic>P<\/jats:italic>\u2009=\u20090.04). Survivors who received CTRT had lower ability to achieve orgasm during sexual activities (<jats:italic>P<\/jats:italic>\u2009=\u20090.04) and they reported disappointment with their overall quality of sex life (<jats:italic>P<\/jats:italic>\u2009=\u20090.002). The number of attempts to initiate sexual intercourse did not differ. Sexual relationships caused none or mild anxiety and the desire to be sexually active was higher after CTRT (<jats:italic>P<\/jats:italic>\u2009=\u20090.05). Multivariable analysis confirmed that orgasmic dysfunction after \u2265400\u2009mg\/m<jats:sup>2<\/jats:sup> of cisplatin and issues in maintaining erection after Tx were independent of retroperitoneal lymph-node dissection (<jats:italic>P\u2009=<\/jats:italic>\u00a00.03 and <jats:italic>P\u2009=<\/jats:italic>\u00a00.04, respectively). Survivors were disappointed with the quality of sex life and had stronger desire to be sexually active independent of age, (<jats:italic>P\u2009=<\/jats:italic>\u00a00.01 and <jats:italic>P\u2009=<\/jats:italic>\u00a00.05, respectively).<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusions<\/jats:title>\n<jats:p>This study identified an impairment in sexual function may represent an issue for long-term GCT survivors. Treatment with chemotherapy plus radiotherapy were associated with disappointment and stronger sexual desire, while a higher cumulative dose of cisplatin may be responsible for orgasmic dysfunction.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s12885-020-07301-6","type":"journal-article","created":{"date-parts":[[2020,8,20]],"date-time":"2020-08-20T08:03:42Z","timestamp":1597910622000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Long-term sexual functioning in germ-cell tumor survivors"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5653-2909","authenticated-orcid":false,"given":"M.","family":"Chovanec","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Vasilkova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Petrikova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Obertova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Palacka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Rejlekova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Z.","family":"Sycova-Mila","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Kalavska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Svetlovska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Mladosievicova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Mardiak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Mego","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,8,20]]},"reference":[{"issue":"21","key":"7301_CR1","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1056\/NEJMra1407550","volume":"371","author":"NH Hanna","year":"2014","unstructured":"Hanna NH, Einhorn LH. Testicular cancer--discoveries and updates. N Engl J Med. 2014;371(21):2005\u201316.","journal-title":"N Engl J Med"},{"issue":"11","key":"7301_CR2","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1038\/nrurol.2016.164","volume":"13","author":"M Chovanec","year":"2016","unstructured":"Chovanec M, Hanna N, Cary KC, Einhorn L, Albany C. Management of stage I testicular germ cell tumours. Nat Rev Urol. 2016;13(11):663\u201373.","journal-title":"Nat Rev Urol"},{"issue":"11","key":"7301_CR3","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1200\/JCO.1990.8.11.1777","volume":"8","author":"LH Einhorn","year":"1990","unstructured":"Einhorn LH. Treatment of testicular cancer: a new and improved model. J Clin Oncol. 1990;8(11):1777\u201381.","journal-title":"J Clin Oncol"},{"issue":"27","key":"7301_CR4","doi-asserted-by":"publisher","first-page":"6549","DOI":"10.1200\/JCO.2005.19.638","volume":"23","author":"GV Kondagunta","year":"2005","unstructured":"Kondagunta GV, Bacik J, Donadio A, Bajorin D, Marion S, Sheinfeld J, et al. Combination of paclitaxel, ifosfamide, and cisplatin is an effective second-line therapy for patients with relapsed testicular germ cell tumors. J Clin Oncol. 2005;23(27):6549\u201355.","journal-title":"J Clin Oncol"},{"issue":"12","key":"7301_CR5","doi-asserted-by":"publisher","first-page":"2413","DOI":"10.1200\/JCO.2000.18.12.2413","volume":"18","author":"RJ Motzer","year":"2000","unstructured":"Motzer RJ, Sheinfeld J, Mazumdar M, Bains M, Mariani T, Bacik J, et al. Paclitaxel, ifosfamide, and cisplatin second-line therapy for patients with relapsed testicular germ cell cancer. J Clin Oncol. 2000;18(12):2413\u20138.","journal-title":"J Clin Oncol"},{"issue":"6","key":"7301_CR6","first-page":"497","volume":"52","author":"J Mardiak","year":"2005","unstructured":"Mardiak J, Salek T, Sycova-Mila Z, Obertova J, Hlavata Z, Mego M, et al. Paclitaxel plus ifosfamide and cisplatin in second-line treatment of germ cell tumors: a phase II study. Neoplasma. 2005;52(6):497\u2013501.","journal-title":"Neoplasma"},{"issue":"10","key":"7301_CR7","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1200\/JCO.2016.69.5395","volume":"35","author":"N Adra","year":"2017","unstructured":"Adra N, Abonour R, Althouse SK, Albany C, Hanna NH, Einhorn LH. High-dose chemotherapy and autologous peripheral-blood stem-cell transplantation for relapsed metastatic germ cell tumors: the Indiana University experience. J Clin Oncol. 2017;35(10):1096\u2013102.","journal-title":"J Clin Oncol"},{"issue":"11","key":"7301_CR8","doi-asserted-by":"publisher","first-page":"2670","DOI":"10.1093\/annonc\/mdx360","volume":"28","author":"M Chovanec","year":"2017","unstructured":"Chovanec M, Abu Zaid M, Hanna N, El-Kouri N, Einhorn LH, Albany C. Long-term toxicity of cisplatin in germ-cell tumor survivors. Ann Oncol. 2017;28(11):2670\u20139.","journal-title":"Ann Oncol"},{"issue":"3","key":"7301_CR9","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1007\/s00520-018-4374-z","volume":"27","author":"A Blouet","year":"2018","unstructured":"Blouet A, Zinger M, Capitain O, Landry S, Bourgeois H, Seegers VT, et al. Sexual quality of life evaluation after treatment among women with breast cancer under 35 years old. Support Care Cancer. 2018;27(3):879.","journal-title":"Support Care Cancer"},{"issue":"1","key":"7301_CR10","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/s10549-018-4894-8","volume":"172","author":"SV Soldera","year":"2018","unstructured":"Soldera SV, Ennis M, Lohmann AE, Goodwin PJ. Sexual health in long-term breast cancer survivors. Breast Cancer Res Treat. 2018;172(1):159.","journal-title":"Breast Cancer Res Treat"},{"issue":"21","key":"7301_CR11","doi-asserted-by":"publisher","first-page":"2160","DOI":"10.1200\/JCO.2017.76.3839","volume":"36","author":"LB Kenney","year":"2018","unstructured":"Kenney LB, Antal Z, Ginsberg JP, Hoppe BS, Bober SL, Yu RN, et al. Improving male reproductive health after childhood, adolescent, and young adult cancer: Progress and future directions for survivorship research. J Clin Oncol. 2018;36(21):2160\u20138.","journal-title":"J Clin Oncol"},{"issue":"4","key":"7301_CR12","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1016\/j.juro.2018.04.077","volume":"200","author":"M Bandak","year":"2018","unstructured":"Bandak M, Lauritsen J, Johansen C, Kreiberg M, Skott JW, Agerbaek M, et al. Sexual function in a Nationwide cohort of 2,260 survivors of testicular cancer after 17 years of Followup. J Urol. 2018;200(4):794.","journal-title":"J Urol"},{"issue":"5","key":"7301_CR13","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1634\/theoncologist.2017-0457","volume":"23","author":"M Chovanec","year":"2018","unstructured":"Chovanec M, Vasilkova L, Setteyova L, Obertova J, Palacka P, Rejlekova K, et al. Long-term cognitive functioning in testicular germ-cell tumor survivors. Oncologist. 2018;23(5):617\u201323.","journal-title":"Oncologist"},{"issue":"Suppl 1","key":"7301_CR14","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1111\/j.1743-6109.2012.02995.x","volume":"10","author":"KE Flynn","year":"2013","unstructured":"Flynn KE, Lin L, Cyranowski JM, Reeve BB, Reese JB, Jeffery DD, et al. Development of the NIH PROMIS (R) sexual function and satisfaction measures in patients with cancer. J Sex Med. 2013;10(Suppl 1):43\u201352.","journal-title":"J Sex Med"},{"issue":"18_suppl","key":"7301_CR15","doi-asserted-by":"publisher","first-page":"LBA10012","DOI":"10.1200\/JCO.2017.35.18_suppl.LBA10012","volume":"35","author":"MIA Zaid","year":"2017","unstructured":"Zaid MIA, Menendez AG, Charif OE, Fung C, Monahan PO, Feldman DR, et al. Adverse health outcomes in relationship to hypogonadism (HG) after platinum-based chemotherapy: a multicenter study of north American testicular cancer survivors (TCS). J Clin Oncol. 2017;35(18_suppl):LBA10012.","journal-title":"J Clin Oncol"},{"issue":"1","key":"7301_CR16","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1200\/JCO.2002.20.1.73","volume":"20","author":"F Joly","year":"2002","unstructured":"Joly F, Heron JF, Kalusinski L, Bottet P, Brune D, Allouache N, et al. Quality of life in long-term survivors of testicular cancer: a population-based case-control study. J Clin Oncol. 2002;20(1):73\u201380.","journal-title":"J Clin Oncol"},{"issue":"5","key":"7301_CR17","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1016\/j.eururo.2007.02.046","volume":"52","author":"AA Dahl","year":"2007","unstructured":"Dahl AA, Bremnes R, Dahl O, Klepp O, Wist E, Fossa SD. Is the sexual function compromised in long-term testicular cancer survivors? Eur Urol. 2007;52(5):1438\u201347.","journal-title":"Eur Urol"},{"issue":"4","key":"7301_CR18","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/j.ejca.2011.11.029","volume":"48","author":"P Rossen","year":"2012","unstructured":"Rossen P, Pedersen AF, Zachariae R, von der Maase H. Sexuality and body image in long-term survivors of testicular cancer. Eur J Cancer. 2012;48(4):571\u20138.","journal-title":"Eur J Cancer"},{"issue":"7","key":"7301_CR19","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.1111\/j.1743-6109.2009.01298.x","volume":"6","author":"J Eberhard","year":"2009","unstructured":"Eberhard J, Stahl O, Cohn-Cedermark G, Cavallin-Stahl E, Giwercman Y, Rylander L, et al. Sexual function in men treated for testicular cancer. J Sex Med. 2009;6(7):1979\u201389.","journal-title":"J Sex Med"},{"issue":"4","key":"7301_CR20","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1016\/j.euf.2018.11.007","volume":"6","author":"M Bandak","year":"2018","unstructured":"Bandak M, Lauritsen J, Johansen C, Kreiberg M, Skott JW, Agerbaek M, et al. Sexual function and quality of life in a National Cohort of survivors of bilateral testicular cancer. Eur Urol Focus. 2018;6(4):711.","journal-title":"Eur Urol Focus"},{"issue":"28","key":"7301_CR21","doi-asserted-by":"publisher","first-page":"4370","DOI":"10.1200\/JCO.2006.10.5296","volume":"25","author":"AW van den Belt-Dusebout","year":"2007","unstructured":"van den Belt-Dusebout AW, de Wit R, Gietema JA, Horenblas S, Louwman MW, Ribot JG, et al. Treatment-specific risks of second malignancies and cardiovascular disease in 5-year survivors of testicular cancer. J Clin Oncol. 2007;25(28):4370\u20138.","journal-title":"J Clin Oncol"},{"issue":"30","key":"7301_CR22","doi-asserted-by":"publisher","first-page":"4649","DOI":"10.1200\/JCO.2010.29.9362","volume":"28","author":"HS Haugnes","year":"2010","unstructured":"Haugnes HS, Wethal T, Aass N, Dahl O, Klepp O, Langberg CW, et al. Cardiovascular risk factors and morbidity in long-term survivors of testicular cancer: a 20-year follow-up study. J Clin Oncol. 2010;28(30):4649\u201357.","journal-title":"J Clin Oncol"},{"issue":"15_suppl","key":"7301_CR23","doi-asserted-by":"publisher","first-page":"9587","DOI":"10.1200\/jco.2014.32.15_suppl.9587","volume":"32","author":"DR Feldman","year":"2014","unstructured":"Feldman DR, Jacobsen EP, Woo K, Steingart R, Fleisher M, Patil S, et al. Acute changes in endothelial function with cisplatin among germ cell tumor (GCT) patients (pts). J Clin Oncol. 2014;32(15_suppl):9587.","journal-title":"J Clin Oncol"},{"key":"7301_CR24","doi-asserted-by":"publisher","first-page":"196","DOI":"10.3389\/fendo.2019.00196","volume":"10","author":"F Pallotti","year":"2019","unstructured":"Pallotti F, Petrozzi A, Cargnelutti F, Radicioni AF, Lenzi A, Paoli D, et al. Long-term follow up of the erectile function of testicular cancer survivors. Front Endocrinol (Lausanne). 2019;10:196.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"7301_CR25","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.urology.2016.02.018","volume":"93","author":"SE Althof","year":"2016","unstructured":"Althof SE, McMahon CG. Contemporary Management of Disorders of male orgasm and ejaculation. Urology. 2016;93:9\u201321.","journal-title":"Urology"},{"issue":"6","key":"7301_CR26","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1007\/s00345-006-0127-6","volume":"24","author":"MA Perelman","year":"2006","unstructured":"Perelman MA, Rowland DL. Retarded ejaculation. World J Urol. 2006;24(6):645\u201352.","journal-title":"World J Urol"},{"issue":"3","key":"7301_CR27","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1080\/00926239708403922","volume":"23","author":"A Keller Ashton","year":"1997","unstructured":"Keller Ashton A, Hamer R, Rosen RC. Serotonin reuptake inhibitor-induced sexual dysfunction and its treatment: a large-scale retrospective study of 596 psychiatric outpatients. J Sex Marital Ther. 1997;23(3):165\u201375.","journal-title":"J Sex Marital Ther"},{"issue":"4","key":"7301_CR28","doi-asserted-by":"publisher","first-page":"686","DOI":"10.21037\/tau.2018.06.20","volume":"7","author":"M Gray","year":"2018","unstructured":"Gray M, Zillioux J, Khourdaji I, Smith RP. Contemporary management of ejaculatory dysfunction. Transl Androl Urol. 2018;7(4):686\u2013702.","journal-title":"Transl Androl Urol"},{"issue":"5","key":"7301_CR29","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1016\/j.juro.2010.06.146","volume":"184","author":"SD Beck","year":"2010","unstructured":"Beck SD, Bey AL, Bihrle R, Foster RS. Ejaculatory status and fertility rates after primary retroperitoneal lymph node dissection. J Urol. 2010;184(5):2078\u201380.","journal-title":"J Urol"},{"issue":"6","key":"7301_CR30","doi-asserted-by":"publisher","first-page":"2526","DOI":"10.1016\/j.juro.2009.01.116","volume":"181","author":"SD Beck","year":"2009","unstructured":"Beck SD, Foster RS, Bihrle R, Einhorn LH, Donohue JP. Long-term outcome for patients with high volume retroperitoneal teratoma undergoing post-chemotherapy surgery. J Urol. 2009;181(6):2526\u201332.","journal-title":"J Urol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-020-07301-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-020-07301-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-020-07301-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,19]],"date-time":"2021-08-19T23:28:59Z","timestamp":1629415739000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-020-07301-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,20]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["7301"],"URL":"https:\/\/doi.org\/10.1186\/s12885-020-07301-6","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,20]]},"assertion":[{"value":"28 October 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 August 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All procedures performed in this study involving human participants were in accordance with the ethical standards of the Institutional Review Board (IRB) (Ethics committee of Slovak National Cancer Institute in Bratislava) and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Written informed consent was obtained from all individual participants included in the study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Michal Chovanec and Michal Mego are Editorial Board Members. The authors declare no other competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"779"}}